One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.

Early-onset GI cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

By Mariam Sunny (Reuters) -Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's ...